Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July

FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated